Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment

Prostate specific membrane antigen targeted radionuclide therapy (PSMA-TRT) is a promising novel treatment for prostate cancer (PCa) patients. However, PSMA-TRT cannot be used for curative intent yet, thus additional research on how to improve the therapeutic efficacy is warranted. A potential way o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruigrok, Eline A. M., Verkaik, Nicole S., de Blois, Erik, de Ridder, Corrina, Stuurman, Debra, Roobol, Stefan J., Van Gent, Dik C., de Jong, Marion, Van Weerden, Wytske M., Nonnekens, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316488/
https://www.ncbi.nlm.nih.gov/pubmed/35887398
http://dx.doi.org/10.3390/ijms23148037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316488/
https://www.ncbi.nlm.nih.gov/pubmed/35887398
http://dx.doi.org/10.3390/ijms23148037

Ejemplares similares